Raymond James Archives

Markets

RJ highlights takeaways from KOL presentations on Profound’s TULSA-PRO

In a new report, Raymond James analyst, Rahul Sarugaser, Ph.D., outlined his five main takeaways from presentations from four key opinion leaders – Yale, UCLA, Mayo Clinic and WellSpan Health – about their clinical...

March 15, 2023

Markets

Raymond James, AGP up Profound Medical PTs as AMA to consider CPT approval

Raymond James raised its price target for Profound Medical (NASDAQ:PROF) to $17 from $15 and reiterated a “strong buy” rating after the company said its application for full CPT-1 reimbursement for TULSA-PRO has been...

March 8, 2023

Executive Moves

Raymond James adds 3 senior bankers to healthcare practice

Raymond James Ltd. (CNW Group/Raymond James Ltd.) Raymond James again expanded its healthcare investment banking practice with the addition of three senior bankers. Joining the firm as managing directors are Jeff...

January 12, 2023

Markets

Raymond James ups Quipt Home Medical PT after acquisition

Raymond James raised its price target for Quipt Home Medical (NASDAQ:QIPT; TSXV:QIPT) to $14 from $10, and reiterated its “outperform” rating after the company acquired Great Elm Healthcare for about $80-million. The...

January 4, 2023

Markets

Raymond James sees catalyst-rich two years ahead for Profound

Raymond James analyst, Rahul Sarugaser, Ph.D., outlined a series of potential catalysts for Profound Medical (NASDAQ:PROF; TSX:PRN), through 2023 and 2024 as it continues to commercialize its TULSA-PRO medical device to...

December 19, 2022

Markets

Raymond James starts POINT Biopharma at OP; PT $10

Raymond James initiated coverage of POINT Biopharma (NASDAQ:PNT) with an “outperform” rating and price target of $10 target. The stock closed at $6.61 on Dec. 13. POINT is a precision oncology company focused on the...

December 14, 2022

Developments

Raymond James sees high likelihood of CPT-1 reimbursement for Profound’s TULSA-PRO

Analyst Rahul Sarugaser, Ph.D., writes that there is a high likelihood that Profound Medical (NASDAQ:PROF) will receive a category-1 CPT code from the Centers for Medicare and Medical Services when it files an...

November 15, 2022

Markets

Raymond James ups Eupraxia PT to $9 (Canadian) on Phase 2 EoE trial

Raymond James raised its price target for Eupraxia Pharmaceuticals (TSXV:EPRX) to $9 (Canadian) from $7 and reiterated its “outperform” rating after the company initiated a Phase 2 clinical trial in eosinophilic...

October 31, 2022

Markets

Raymond James resumes coverage of Eupraxia at OP; PT $7 (Canadian)

Raymond James resumed coverage of Eupraxia Pharmaceuticals (TSX:EPRX) with an “outperform” rating and $7 (Canadian) price target. The stock closed at $1.36 on June 8. Eupraxia’s lead clinical candidate, EP-104IAR...

June 9, 2022

Markets

Raymond James cuts Cardiol Therapeutics to MP; PT to $4 (Canadian)

Raymond James downgraded Cardiol Therapeutics (TSX:CRDL) to “market perform” from “outperform” and trimmed its price target to $4 (Canadian) from $5, citing a slower than expected enrollment in Cardiol’s LANCER clinical...

March 16, 2022

Tag - Raymond James

RJ highlights takeaways from KOL presentations on Profound’s TULSA-PRO

Raymond James, AGP up Profound Medical PTs as AMA to consider CPT approval

Raymond James adds 3 senior bankers to healthcare practice

Raymond James ups Quipt Home Medical PT after acquisition

Raymond James sees catalyst-rich two years ahead for Profound

Raymond James starts POINT Biopharma at OP; PT $10

Raymond James sees high likelihood of CPT-1 reimbursement for Profound’s TULSA-PRO

Raymond James ups Eupraxia PT to $9 (Canadian) on Phase 2 EoE trial

Raymond James resumes coverage of Eupraxia at OP; PT $7 (Canadian)

Raymond James cuts Cardiol Therapeutics to MP; PT to $4 (Canadian)

General

More